APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza NA Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Influenza NA Inhibitor Market Analysis and Forecast 2026-2032

2 January 2026194 pages

Choose your research edition.

Industry ResearchInfluenza NA Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza NA Inhibitor Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Influenza NA Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza NA Inhibitor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza NA Inhibitor Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Influenza NA Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Influenza NA Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Influenza NA Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Influenza NA Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Influenza NA Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Influenza NA Inhibitor include ATK Chemical, Chemwill Asia Co.,Ltd., Green Cross, Moksha8 Pharma, NeoPharm, Shionogi Co., GlaxoSmithKline, Henan DaKen Chemical and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Influenza NA Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Influenza NA Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza NA Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza NA Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Influenza NA Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Influenza NA Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Influenza NA Inhibitor Segment by Company

ATK Chemical

Chemwill Asia Co.,Ltd.

Green Cross

Moksha8 Pharma

NeoPharm

Shionogi Co.

GlaxoSmithKline

Henan DaKen Chemical

Roche

Influenza NA Inhibitor Segment by Type

Zanamivir

Peramivir

Oseltamivir

Influenza NA Inhibitor Segment by Application

Influenza A Treatment

Influenza B Treatment

Influenza NA Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza NA Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza NA Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza NA Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Influenza NA Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza NA Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Influenza NA Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Zanamivir Major Manufacturers Table 3. Peramivir Major Manufacturers Table 4. Oseltamivir Major Manufacturers Table 5. Global Influenza NA Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Influenza A Treatment Major Manufacturers Table 7. Influenza B Treatment Major Manufacturers Table 8. Influenza NA Inhibitor Industry Trends Table 9. Influenza NA Inhibitor Industry Drivers Table 10. Influenza NA Inhibitor Industry Opportunities and Challenges Table 11. Influenza NA Inhibitor Industry Restraints Table 12. Global Influenza NA Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Influenza NA Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Influenza NA Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Influenza NA Inhibitor Revenue Market Share by Region (2021-2026) Table 16. Global Influenza NA Inhibitor Revenue Market Share by Region (2027-2032) Table 17. Global Influenza NA Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 18. Global Influenza NA Inhibitor Sales by Region (2021-2026) & (Tons) Table 19. Global Influenza NA Inhibitor Sales by Region (2027-2032) & (Tons) Table 20. Global Influenza NA Inhibitor Sales Market Share by Region (2021-2026) Table 21. Global Influenza NA Inhibitor Sales Market Share by Region (2027-2032) Table 22. Global Influenza NA Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Influenza NA Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Influenza NA Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 26. Global Influenza NA Inhibitor Sales Price (US$/Kg) of Manufacturers (2021-2026) Table 27. Global Influenza NA Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Influenza NA Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Influenza NA Inhibitor Manufacturers, Product Type & Application Table 30. Global Influenza NA Inhibitor Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Influenza NA Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Influenza NA Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Influenza NA Inhibitor Revenue Market Share by Type (2021-2026) Table 37. Global Influenza NA Inhibitor Revenue Market Share by Type (2027-2032) Table 38. Global Influenza NA Inhibitor Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 39. Global Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons) Table 40. Global Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons) Table 41. Global Influenza NA Inhibitor Sales Market Share by Type (2021-2026) Table 42. Global Influenza NA Inhibitor Sales Market Share by Type (2027-2032) Table 43. Global Influenza NA Inhibitor Price by Type (2021-2026) & (US$/Kg) Table 44. Global Influenza NA Inhibitor Price by Type (2027-2032) & (US$/Kg) Table 45. Global Influenza NA Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Influenza NA Inhibitor Revenue Market Share by Application (2021-2026) Table 49. Global Influenza NA Inhibitor Revenue Market Share by Application (2027-2032) Table 50. Global Influenza NA Inhibitor Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 51. Global Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons) Table 52. Global Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons) Table 53. Global Influenza NA Inhibitor Sales Market Share by Application (2021-2026) Table 54. Global Influenza NA Inhibitor Sales Market Share by Application (2027-2032) Table 55. Global Influenza NA Inhibitor Price by Application (2021-2026) & (US$/Kg) Table 56. Global Influenza NA Inhibitor Price by Application (2027-2032) & (US$/Kg) Table 57. ATK Chemical Company Information Table 58. ATK Chemical Business Overview Table 59. ATK Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 60. ATK Chemical Influenza NA Inhibitor Product Portfolio Table 61. ATK Chemical Recent Development Table 62. Chemwill Asia Co.,Ltd. Company Information Table 63. Chemwill Asia Co.,Ltd. Business Overview Table 64. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 65. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio Table 66. Chemwill Asia Co.,Ltd. Recent Development Table 67. Green Cross Company Information Table 68. Green Cross Business Overview Table 69. Green Cross Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 70. Green Cross Influenza NA Inhibitor Product Portfolio Table 71. Green Cross Recent Development Table 72. Moksha8 Pharma Company Information Table 73. Moksha8 Pharma Business Overview Table 74. Moksha8 Pharma Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 75. Moksha8 Pharma Influenza NA Inhibitor Product Portfolio Table 76. Moksha8 Pharma Recent Development Table 77. NeoPharm Company Information Table 78. NeoPharm Business Overview Table 79. NeoPharm Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 80. NeoPharm Influenza NA Inhibitor Product Portfolio Table 81. NeoPharm Recent Development Table 82. Shionogi Co. Company Information Table 83. Shionogi Co. Business Overview Table 84. Shionogi Co. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 85. Shionogi Co. Influenza NA Inhibitor Product Portfolio Table 86. Shionogi Co. Recent Development Table 87. GlaxoSmithKline Company Information Table 88. GlaxoSmithKline Business Overview Table 89. GlaxoSmithKline Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 90. GlaxoSmithKline Influenza NA Inhibitor Product Portfolio Table 91. GlaxoSmithKline Recent Development Table 92. Henan DaKen Chemical Company Information Table 93. Henan DaKen Chemical Business Overview Table 94. Henan DaKen Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 95. Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio Table 96. Henan DaKen Chemical Recent Development Table 97. Roche Company Information Table 98. Roche Business Overview Table 99. Roche Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 100. Roche Influenza NA Inhibitor Product Portfolio Table 101. Roche Recent Development Table 102. North America Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons) Table 105. North America Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons) Table 106. North America Influenza NA Inhibitor Sales Price by Type (2021-2026) & (US$/Kg) Table 107. North America Influenza NA Inhibitor Sales Price by Type (2027-2032) & (US$/Kg) Table 108. North America Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons) Table 111. North America Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons) Table 112. North America Influenza NA Inhibitor Sales Price by Application (2021-2026) & (US$/Kg) Table 113. North America Influenza NA Inhibitor Sales Price by Application (2027-2032) & (US$/Kg) Table 114. North America Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Influenza NA Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 116. North America Influenza NA Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 117. North America Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 118. North America Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons) Table 119. North America Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons) Table 120. North America Influenza NA Inhibitor Sales Price by Country (2021-2026) & (US$/Kg) Table 121. North America Influenza NA Inhibitor Sales Price by Country (2027-2032) & (US$/Kg) Table 122. United States Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 123. Canada Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 124. Europe Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons) Table 127. Europe Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons) Table 128. Europe Influenza NA Inhibitor Sales Price by Type (2021-2026) & (US$/Kg) Table 129. Europe Influenza NA Inhibitor Sales Price by Type (2027-2032) & (US$/Kg) Table 130. Europe Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons) Table 133. Europe Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons) Table 134. Europe Influenza NA Inhibitor Sales Price by Application (2021-2026) & (US$/Kg) Table 135. Europe Influenza NA Inhibitor Sales Price by Application (2027-2032) & (US$/Kg) Table 136. Europe Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Europe Influenza NA Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. Europe Influenza NA Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. Europe Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 140. Europe Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons) Table 141. Europe Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons) Table 142. Europe Influenza NA Inhibitor Sales Price by Country (2021-2026) & (US$/Kg) Table 143. Europe Influenza NA Inhibitor Sales Price by Country (2027-2032) & (US$/Kg) Table 144. Germany Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 145. France Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 146. U.K. Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 147. Italy Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 148. Netherlands Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 149. China Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 150. China Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 151. China Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons) Table 152. China Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons) Table 153. China Influenza NA Inhibitor Sales Price by Type (2021-2026) & (US$/Kg) Table 154. China Influenza NA Inhibitor Sales Price by Type (2027-2032) & (US$/Kg) Table 155. China Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 156. China Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 157. China Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons) Table 158. China Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons) Table 159. China Influenza NA Inhibitor Sales Price by Application (2021-2026) & (US$/Kg) Table 160. China Influenza NA Inhibitor Sales Price by Application (2027-2032) & (US$/Kg) Table 161. Asia Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 162. Asia Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 163. Asia Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons) Table 164. Asia Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons) Table 165. Asia Influenza NA Inhibitor Sales Price by Type (2021-2026) & (US$/Kg) Table 166. Asia Influenza NA Inhibitor Sales Price by Type (2027-2032) & (US$/Kg) Table 167. Asia Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 168. Asia Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons) Table 170. Asia Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons) Table 171. Asia Influenza NA Inhibitor Sales Price by Application (2021-2026) & (US$/Kg) Table 172. Asia Influenza NA Inhibitor Sales Price by Application (2027-2032) & (US$/Kg) Table 173. Asia Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Influenza NA Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. Asia Influenza NA Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. Asia Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 177. Asia Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons) Table 178. Asia Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons) Table 179. Asia Influenza NA Inhibitor Sales Price by Country (2021-2026) & (US$/Kg) Table 180. Asia Influenza NA Inhibitor Sales Price by Country (2027-2032) & (US$/Kg) Table 181. Japan Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 182. South Korea Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 183. India Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 184. Australia Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 185. China Taiwan Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 186. Southeast Asia Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 187. SAMEA Influenza NA Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 188. SAMEA Influenza NA Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 189. SAMEA Influenza NA Inhibitor Sales by Type (2021-2026) & (Tons) Table 190. SAMEA Influenza NA Inhibitor Sales by Type (2027-2032) & (Tons) Table 191. SAMEA Influenza NA Inhibitor Sales Price by Type (2021-2026) & (US$/Kg) Table 192. SAMEA Influenza NA Inhibitor Sales Price by Type (2027-2032) & (US$/Kg) Table 193. SAMEA Influenza NA Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 194. SAMEA Influenza NA Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 195. SAMEA Influenza NA Inhibitor Sales by Application (2021-2026) & (Tons) Table 196. SAMEA Influenza NA Inhibitor Sales by Application (2027-2032) & (Tons) Table 197. SAMEA Influenza NA Inhibitor Sales Price by Application (2021-2026) & (US$/Kg) Table 198. SAMEA Influenza NA Inhibitor Sales Price by Application (2027-2032) & (US$/Kg) Table 199. SAMEA Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. SAMEA Influenza NA Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. SAMEA Influenza NA Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. SAMEA Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 203. SAMEA Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons) Table 204. SAMEA Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons) Table 205. SAMEA Influenza NA Inhibitor Sales Price by Country (2021-2026) & (US$/Kg) Table 206. SAMEA Influenza NA Inhibitor Sales Price by Country (2027-2032) & (US$/Kg) Table 207. Brazil Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 208. Argentina Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 209. Chile Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 210. Colombia Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 211. Peru Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 212. Saudi Arabia Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 213. Israel Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 214. UAE Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 215. Turkey Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 216. Iran Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 217. Egypt Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Table 218. Key Raw Materials Table 219. Raw Materials Key Suppliers Table 220. Influenza NA Inhibitor Distributors List Table 221. Influenza NA Inhibitor Customers List Table 222. Research Programs/Design for This Report Table 223. Authors List of This Report Table 224. Secondary Sources Table 225. Primary Sources List of Figures Figure 1. Influenza NA Inhibitor Image Figure 2. Global Influenza NA Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza NA Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Zanamivir Image Figure 5. Peramivir Image Figure 6. Oseltamivir Image Figure 7. Global Influenza NA Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Influenza NA Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 9. Influenza A Treatment Image Figure 10. Influenza B Treatment Image Figure 11. Global Influenza NA Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Influenza NA Inhibitor Revenue (2021-2032) & (US$ Million) Figure 13. Global Influenza NA Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Influenza NA Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Influenza NA Inhibitor Revenue Market Share by Region (2021-2032) Figure 16. Global Influenza NA Inhibitor Sales (2021-2032) & (Tons) Figure 17. Global Influenza NA Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 18. Global Influenza NA Inhibitor Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Influenza NA Inhibitor Sales YoY (2021-2032) & (Tons) Figure 20. Europe Influenza NA Inhibitor Sales YoY (2021-2032) & (Tons) Figure 21. China Influenza NA Inhibitor Sales YoY (2021-2032) & (Tons) Figure 22. Asia (Excluding China) Influenza NA Inhibitor Sales YoY (2021-2032) & (Tons) Figure 23. South America, Middle East and Africa Influenza NA Inhibitor Sales YoY (2021-2032) & (Tons) Figure 24. Global Influenza NA Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Influenza NA Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Influenza NA Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Influenza NA Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Influenza NA Inhibitor Revenue Market Share by Type (2021-2032) Figure 30. Global Influenza NA Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 31. Global Influenza NA Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Influenza NA Inhibitor Sales Market Share by Type (2021-2032) Figure 33. Global Influenza NA Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Influenza NA Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Influenza NA Inhibitor Revenue Market Share by Application (2021-2032) Figure 36. Global Influenza NA Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 37. Global Influenza NA Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Influenza NA Inhibitor Sales Market Share by Application (2021-2032) Figure 39. North America Influenza NA Inhibitor Revenue Share by Type (2021-2032) Figure 40. North America Influenza NA Inhibitor Sales Share by Type (2021-2032) Figure 41. North America Influenza NA Inhibitor Revenue Share by Application (2021-2032) Figure 42. North America Influenza NA Inhibitor Sales Share by Application (2021-2032) Figure 43. North America Influenza NA Inhibitor Revenue Share by Country (2021-2032) Figure 44. North America Influenza NA Inhibitor Sales Share by Country (2021-2032) Figure 45. Europe Influenza NA Inhibitor Revenue Share by Type (2021-2032) Figure 46. Europe Influenza NA Inhibitor Sales Share by Type (2021-2032) Figure 47. Europe Influenza NA Inhibitor Revenue Share by Application (2021-2032) Figure 48. Europe Influenza NA Inhibitor Sales Share by Application (2021-2032) Figure 49. Europe Influenza NA Inhibitor Revenue Share by Country (2021-2032) Figure 50. Europe Influenza NA Inhibitor Sales Share by Country (2021-2032) Figure 51. China Influenza NA Inhibitor Revenue Share by Type (2021-2032) Figure 52. China Influenza NA Inhibitor Sales Share by Type (2021-2032) Figure 53. China Influenza NA Inhibitor Revenue Share by Application (2021-2032) Figure 54. China Influenza NA Inhibitor Sales Share by Application (2021-2032) Figure 55. Asia Influenza NA Inhibitor Revenue Share by Type (2021-2032) Figure 56. Asia Influenza NA Inhibitor Sales Share by Type (2021-2032) Figure 57. Asia Influenza NA Inhibitor Revenue Share by Application (2021-2032) Figure 58. Asia Influenza NA Inhibitor Sales Share by Application (2021-2032) Figure 59. Asia Influenza NA Inhibitor Revenue Share by Country (2021-2032) Figure 60. Asia Influenza NA Inhibitor Sales Share by Country (2021-2032) Figure 61. SAMEA Influenza NA Inhibitor Revenue Share by Type (2021-2032) Figure 62. SAMEA Influenza NA Inhibitor Sales Share by Type (2021-2032) Figure 63. SAMEA Influenza NA Inhibitor Revenue Share by Application (2021-2032) Figure 64. SAMEA Influenza NA Inhibitor Sales Share by Application (2021-2032) Figure 65. SAMEA Influenza NA Inhibitor Revenue Share by Country (2021-2032) Figure 66. SAMEA Influenza NA Inhibitor Sales Share by Country (2021-2032) Figure 67. Influenza NA Inhibitor Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Influenza NA Inhibitor Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Zanamivir
  • Peramivir
  • Oseltamivir
Applications
  • Influenza A Treatment
  • Influenza B Treatment
Companies covered
  • ATK Chemical
  • Chemwill Asia Co.,Ltd.
  • Green Cross
  • Moksha8 Pharma
  • NeoPharm
  • Shionogi Co.
  • GlaxoSmithKline
  • Henan DaKen Chemical
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Influenza NA Inhibitor Market by Type
  3. 1.2.1 Global Influenza NA Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Zanamivir
  5. 1.2.3 Peramivir
  6. 1.2.4 Oseltamivir
  7. 1.3 Influenza NA Inhibitor Market by Application
  8. 1.3.1 Global Influenza NA Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Influenza A Treatment
  10. 1.3.3 Influenza B Treatment
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Influenza NA Inhibitor Market Dynamics
  1. 2.1 Influenza NA Inhibitor Industry Trends
  2. 2.2 Influenza NA Inhibitor Industry Drivers
  3. 2.3 Influenza NA Inhibitor Industry Opportunities and Challenges
  4. 2.4 Influenza NA Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Influenza NA Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Influenza NA Inhibitor Revenue by Region
  3. 3.2.1 Global Influenza NA Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Influenza NA Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global Influenza NA Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global Influenza NA Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Influenza NA Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Influenza NA Inhibitor Sales by Region
  9. 3.4.1 Global Influenza NA Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Influenza NA Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global Influenza NA Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global Influenza NA Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Influenza NA Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global Influenza NA Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Influenza NA Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Influenza NA Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Influenza NA Inhibitor Sales by Manufacturers
  6. 4.2.1 Global Influenza NA Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Influenza NA Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Influenza NA Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Influenza NA Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Influenza NA Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Influenza NA Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global Influenza NA Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Influenza NA Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 Influenza NA Inhibitor Tier 1, Tier 2, and Tier 3
5 Influenza NA Inhibitor Market by Type
  1. 5.1 Global Influenza NA Inhibitor Revenue by Type
  2. 5.1.1 Global Influenza NA Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Influenza NA Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Influenza NA Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Influenza NA Inhibitor Sales by Type
  6. 5.2.1 Global Influenza NA Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza NA Inhibitor Sales by Type (2021-2032) & (Tons)
  8. 5.2.3 Global Influenza NA Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global Influenza NA Inhibitor Price by Type
6 Influenza NA Inhibitor Market by Application
  1. 6.1 Global Influenza NA Inhibitor Revenue by Application
  2. 6.1.1 Global Influenza NA Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Influenza NA Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Influenza NA Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Influenza NA Inhibitor Sales by Application
  6. 6.2.1 Global Influenza NA Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Influenza NA Inhibitor Sales by Application (2021-2032) & (Tons)
  8. 6.2.3 Global Influenza NA Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global Influenza NA Inhibitor Price by Application
7 Company Profiles
  1. 7.1 ATK Chemical
  2. 7.1.1 ATK Chemical Company Information
  3. 7.1.2 ATK Chemical Business Overview
  4. 7.1.3 ATK Chemical Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
  6. 7.1.5 ATK Chemical Recent Developments
  7. 7.2 Chemwill Asia Co.,Ltd.
  8. 7.2.1 Chemwill Asia Co.,Ltd. Company Information
  9. 7.2.2 Chemwill Asia Co.,Ltd. Business Overview
  10. 7.2.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
  12. 7.2.5 Chemwill Asia Co.,Ltd. Recent Developments
  13. 7.3 Green Cross
  14. 7.3.1 Green Cross Company Information
  15. 7.3.2 Green Cross Business Overview
  16. 7.3.3 Green Cross Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Green Cross Influenza NA Inhibitor Product Portfolio
  18. 7.3.5 Green Cross Recent Developments
  19. 7.4 Moksha8 Pharma
  20. 7.4.1 Moksha8 Pharma Company Information
  21. 7.4.2 Moksha8 Pharma Business Overview
  22. 7.4.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
  24. 7.4.5 Moksha8 Pharma Recent Developments
  25. 7.5 NeoPharm
  26. 7.5.1 NeoPharm Company Information
  27. 7.5.2 NeoPharm Business Overview
  28. 7.5.3 NeoPharm Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 NeoPharm Influenza NA Inhibitor Product Portfolio
  30. 7.5.5 NeoPharm Recent Developments
  31. 7.6 Shionogi Co.
  32. 7.6.1 Shionogi Co. Company Information
  33. 7.6.2 Shionogi Co. Business Overview
  34. 7.6.3 Shionogi Co. Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
  36. 7.6.5 Shionogi Co. Recent Developments
  37. 7.7 GlaxoSmithKline
  38. 7.7.1 GlaxoSmithKline Company Information
  39. 7.7.2 GlaxoSmithKline Business Overview
  40. 7.7.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
  42. 7.7.5 GlaxoSmithKline Recent Developments
  43. 7.8 Henan DaKen Chemical
  44. 7.8.1 Henan DaKen Chemical Company Information
  45. 7.8.2 Henan DaKen Chemical Business Overview
  46. 7.8.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
  48. 7.8.5 Henan DaKen Chemical Recent Developments
  49. 7.9 Roche
  50. 7.9.1 Roche Company Information
  51. 7.9.2 Roche Business Overview
  52. 7.9.3 Roche Influenza NA Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Roche Influenza NA Inhibitor Product Portfolio
  54. 7.9.5 Roche Recent Developments
8 North America
  1. 8.1 North America Influenza NA Inhibitor Market Size by Type
  2. 8.1.1 North America Influenza NA Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America Influenza NA Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America Influenza NA Inhibitor Price by Type (2021-2032)
  5. 8.2 North America Influenza NA Inhibitor Market Size by Application
  6. 8.2.1 North America Influenza NA Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America Influenza NA Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America Influenza NA Inhibitor Price by Application (2021-2032)
  9. 8.3 North America Influenza NA Inhibitor Market Size by Country
  10. 8.3.1 North America Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Influenza NA Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Influenza NA Inhibitor Market Size by Type
  2. 9.1.1 Europe Influenza NA Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe Influenza NA Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe Influenza NA Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe Influenza NA Inhibitor Market Size by Application
  6. 9.2.1 Europe Influenza NA Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe Influenza NA Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe Influenza NA Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe Influenza NA Inhibitor Market Size by Country
  10. 9.3.1 Europe Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Influenza NA Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Influenza NA Inhibitor Market Size by Type
  2. 10.1.1 China Influenza NA Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China Influenza NA Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China Influenza NA Inhibitor Price by Type (2021-2032)
  5. 10.2 China Influenza NA Inhibitor Market Size by Application
  6. 10.2.1 China Influenza NA Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China Influenza NA Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China Influenza NA Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Influenza NA Inhibitor Market Size by Type
  2. 11.1.1 Asia Influenza NA Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia Influenza NA Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia Influenza NA Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia Influenza NA Inhibitor Market Size by Application
  6. 11.2.1 Asia Influenza NA Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia Influenza NA Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia Influenza NA Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia Influenza NA Inhibitor Market Size by Country
  10. 11.3.1 Asia Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Influenza NA Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Influenza NA Inhibitor Market Size by Type
  2. 12.1.1 SAMEA Influenza NA Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Influenza NA Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Influenza NA Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA Influenza NA Inhibitor Market Size by Application
  6. 12.2.1 SAMEA Influenza NA Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Influenza NA Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Influenza NA Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA Influenza NA Inhibitor Market Size by Country
  10. 12.3.1 SAMEA Influenza NA Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Influenza NA Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Influenza NA Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Influenza NA Inhibitor Value Chain Analysis
  2. 13.1.1 Influenza NA Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Influenza NA Inhibitor Production Mode & Process
  6. 13.2 Influenza NA Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Influenza NA Inhibitor Distributors
  9. 13.2.3 Influenza NA Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst